However, there is still a gap in our understanding of mechanisms underlying AHR and a potential to combine these established therapies with inhibitors of the IL-31RA-CHRM3 axis to achieve effective inhibition of AHR, inflammation and goblet cell hyperplasia in asthma. This evidence concerns the gene CHRM3 and asthma.